Global STING Pathway Targeting Therapeutics and Technologies Market Report 2020-2030

Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030" report has been added to *ResearchAndMarkets.com's* offering.

The "STING Pathway Targeting Therapeutics and Technologies" report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. Basically, the STING pathway offers an alternative approach to harnessing the immune system, in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders. The aforementioned therapeutic benefits can be achieved using modulators of the STING/cGAS-pathway. Over the years, a number of such modulators, capable of either activating or downregulating the STING pathway, have been developed. More than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders.

The popularity of STING pathway modulation and growing interest of drug developers in this upcoming field of therapeutics is evident in the rising volume of affiliated scientific literature (1,000+ related articles on NCBI's PubMed portal since 2015). Moreover, capital investments worth over USD 2.6 billion have been made by various private and public sector investors to fund product development activity. In addition, there have been multiple, high value technology licensing deals in this domain, since 2015.

As a result, there has been a considerable rise in number of companies taking initiatives in this field, over the past 4-5 years alone. Interestingly, several big pharma players are also actively evaluating multiple STING agonists/antagonists. It is also worth noting that molecular research into the pathogenesis of the novel SARS-CoV-2 viral strain suggests that COVID-19 may be a STING-related disorder, characterized by delayed over-secretion of IFN-?.

STING, in humans, is mostly expressed in lung alveolar epithelial cells, endothelial cells, and spleen cells, which are considered crucial for COVID-19 pathogenesis. Therefore, rapid assessments of STING polymorphisms may actually be useful in identifying individuals who are at high risks of contracting a severe form of this infection. Further, a better understanding of the underlying mechanisms associated with the novel coronavirus induced STING-pathway over-activation, may enable the development of potential therapeutic candidates against COVID-19.

Currently, there are no approved STING pathway-targeting drugs/therapy products in the market. However, some promising leads are anticipated to be launched over the coming decade, following which the market is projected to grow at a substantial pace.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of STING pathway modulators. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030.

*Key Topics Covered:*

*1. PREFACE*
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

*2. EXECUTIVE SUMMARY*

*3. INTRODUCTION*
3.1. Stimulator of Interferon Genes (STING) Pathway
3.2. STING Signaling
3.3. STING Pathway Modulators
3.4. Key Variants of STING
3.5. Non-immunological Functions of the STING Pathway
3.6. Concluding Remarks

*4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE*
4.1. Chapter Overview
4.2. STING Pathway Targeting Therapeutics: Development Pipeline
4.3. STING Pathway Targeting Therapeutics: Developer Landscape
4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials

*5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE*
5.1. Chapter Overview
5.2. STING Pathway Targeting Technologies: List of Technology Developers

*6. COMPANY PROFILES*
6.1. Chapter Overview
6.2 STING Agonist Developers
6.2.1. Aduro Biotech
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: ADU-S100 (MIW815)
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bristol-Myers Squibb
6.2.3. Eisai
6.2.4 GlaxoSmithKline
6.2.5. ImmuneSensor Therapeutics
6.2.6. Merck
6.2.7. Noxopharm
6.2.8. Spring Bank Pharmaceuticals
6.2.9. Synlogic
6.3. STING Antagonist Developers
6.3.1 Avammune Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor Therapeutics
6.3.4. Nimbus Therapeutics
6.3.5. Sirenas
6.3.6. Spring Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe Therapeutics

*7. ACADEMIC GRANT ANALYSIS*
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting Therapeutics: List of Academic Grants
7.4. Grant Attractiveness Analysis

*8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS*
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big Pharma Players
8.4. Benchmarking Big Pharma Players

*9. START-UP HEALTH INDEXING*
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups

*10. PUBLICATION ANALYSIS*
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. STING Pathway Targeting Therapeutics: Recent Publications

*11. PARTNERSHIPS AND COLLABORATIONS*
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics: Recent Partnerships

*12. FUNDING AND INVESTMENT ANALYSIS*
12.1. Chapter Overview
12.2. Types of Funding
12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances
12.4. Concluding Remarks

*13. MARKET SIZING AND OPPORTUNITY ANALYSIS*
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology

*14. EXECUTIVE INSIGHTS*

*15. CONCLUDING REMARKS*
15.1. Chapter Overview
15.2. Key Takeaways

*16. APPENDIX 1: TABULATED DATA

Companies Mentioned
*

· 6 Dimensions Capital
· Aalborg University
· Aarhus University
· AbbVie
· Abingworth
· Academia Sinica
· Actym Therapeutics
· Aduro Biotech
· Aescap 2.0
· AJU IB Investment
· Alaska Permanent Fund
· Alexandria Venture Investments
· All India Institute of Medical Sciences
· Allergan
· Ally Bridge Group
· Almac Diagnostics
· Alpine BioVentures
· Atlas Venture
· Amgen
· Anhui University of Science and Technology
· Arbutus Biopharma
· ARCH Venture Partners
· Arctic Aurora LifeScience
· Arix Bioscience
· Arizona State University
· Army Medical University
· Arrowpoint Partners
· Artimmune
· Astellas Pharma
· AstraZeneca
· Avammune Therapeutics
· Baruch S. Blumberg Institute
· Bayer
· Baylor University Medical Center
· Beatson Institute
· BellBrook Labs
· Beth Israel Deaconess Medical Center
· Bicycle Therapeutics
· Bill & Melinda Gates Foundation
· Biogen
· BioInnovation Institute
· Institut de Recerca Biomedica de Lleida (IRBLleida)
· BioNovion
· Boehringer Ingelheim
· Boston Children's Hospital
· Boston University
· Boxer Capital
· Bpifrance
· Brigham And Women's Hospital
· Bristol-Myers Squibb
· BWG Invest
· California Institute for Biomedical Research
· Cambridge Innovation Capital
· The Beatson Institute
· Cancer Therapeutics CRC
· Canterbury Urology Research Trust
· Casdin Capital
· Case Western Reserve University
· Celgene
· Central South University
· Center for AIDS Research
· CHA University
· Chaim Sheba Medical Center
· Charite Universitatsmedizin Berlin
· Charles River Laboratories
· Charles University
· Chengwei Capital
· China Pharmaceutical University
· Chinese Academy of Agricultural Sciences
· Chinese Academy of Medical Sciences
· Chongqing Medical University
· Chulalongkorn University
· Cincinnati Childern's Hospital Medical Center
· CLI Ventures
· Clough Capital Partners
· Codiak BioSciences
· College of Biotechnology Southwest University
· Columbia University Medical Center
· CordenPharma
· Cristal Therapeutics
· CSL
· CST Investment Funds
· Curadev Pharma
· Curative Ventures
· Czech Academy of Sciences
· Daiichi Sankyo
· Dalhousie University
· Dana-Farber Cancer Institute
· David Geffen School of Medicine
· Deaconess Medical Center
· Deerfield Management
· Dermatology Hospital of Fuzhou
· Dezful University of Medical Sciences
· DiscoveryBioMed
· Duke University Medical Center
· Ecole polytechnique federale de Lausanne
· EcoR1 Capital
· Ege University
· Eight Roads Ventures
· Eisai
· Eli Lilly
· Emory University School of Medicine
· Eulji University School of Medicine
· European Institute of Oncology
· Evonik Nutrition & Care
· Feinstein Institutes for Medical Research
· Ferring Pharmaceuticals
· Fidelity Biosciences
· Flagship Pioneering
· Florida State University
· Fluorinov Pharma
· Fondazione IRCCS Istituto Nazionale dei Tumori
· Foresite Capital
· Fox Chase Cancer Center
· F-Prime Capital
· Franklin Advisers
· Frazier Healthcare Partners
· Fredrick National Laboratory for Cancer Research
· Fudan University
· Fujian Medical University
· Fund+
· Gachon University
· Geisel School of Medicine
· Genentech
· GenesisCare
· George Clinical
· Georges-Francois Leclerc Cancer Center- UNICNACER
· Ghent University Hospital
· Gifu University Graduate School of Medicine
· Gilead Sciences
· Ginkgo Bioworks
· GlaxoSmithKline
· Green Park & Golf Ventures
· Griffith University
· Guangzhou Medical University
· Guilin Medical University
· Gunma University
· H3Biomedicine
· Hacettepe University
· Hackensack University John Theurer Cancer Center
· Hallym University
· Harbin Veterinary Research Institute
· Harvard Medical School
· HBM Partners
· Health Wildcatters
· Helmholtz Centre for Infection Research
· Henan Agricultural University
· HitGen
· Hong Kong University of Science & Technology
· Huntsman Cancer Institute
· Icahn School of Medicine at Mount Sinai
· IFM Therapeutics
· ImaBiotech
· ImmuneSensor Therapeutics
· IMMvention Therapeutix
· Inflammatory Bowel Disease Center
· Inserm
· Institute of Materia Medica
· Institute of Radiation Biology
· Institut Curie
· Gustave Roussy
· Institute for Personalized Medicine
· Institute of Macromolecular Chemistry ASCR
· Institute of Pathogen Biology
· InvivoGen
· Invus
· Iowa State University
· iOx Therapeutics
· IQVIA
· Istanbul Technical University
· Istituto Superiore di Sanita
· iTeos Therapeutics
· James Graham Brown Cancer Center
· Janus Capital Management
· Japanese Foundation for Cancer Research
· Jazz Pharmaceuticals
· Jennison Associates
· Jilin University
· Johns Hopkins University School of Medicine
· Juntendo University School of Medicine
· Kalinga Institute of Industrial Technology
· Kangwon National University
· Karmanos Cancer Institute
· Karol Marcinkowski University of Medical Sciences
· Karolinska Institute
· Kazia Therapeutics
· Keystone Symposia
· Kindeva Drug Delivery
· Kobe University
· Korea Advanced Institute of Science and Technology
· KU Leuven
· Kuang Tien General Hospital Cancer Center
· Kunming University of Science and Technology
· RIKEN Center for Integrative Medical Sciences Laboratory for Cell Signaling
· Lerner Research Institute
· Les Laboratoires Servier
· LIDDS
· Life Science Venture Capital Management
· Lightstone Ventures
· Linkoping University
· Longwood Fund
· Lund University
· Magee- Womens Research Institute
· Maria Sklodowska-Curie National Research Institute of Oncology
· Mary Crowley Cancer Research
· Massachusetts General Hospital
· Massachusetts Green High Performance Computing Center
· Massachusetts Institute of Technology
· Max Planck Institute for Immunobiology and Epigenetics
· Mayo Clinic
· Medical College of Wisconsin
· Medigen
· Medison Finance
· Meharry Medical College
· Memorial Sloan Kettering Cancer Center
· Merck
· Mersana Therapeutics
· Michigan State University
· Mirna Therapeutics
· Moffitt Cancer Center
· Monash University
· Morningside Group
· Mount Sinai Hospital
· MPM Capital
· MUSC Hollings Cancer Center
· Nanchang University
· Nanjing Agricultural University
· Nanjing Medical University
· Nankai Univeristy
· Nanobiotix
· National Center of Biomedical Analysis
· National Institutes of Biomedical Innovation, Health and Nutrition
· National Institutes of Health
· National Tsing Hua University
· National Yang-Ming University
· New Enterprise Associates
· New York Medical College
· Newcastle University
· NEXT Oncology
· Nimbus Therapeutics
· Ningxia university
· Northwest A&F University
· Northwestern University
· Novartis
· Novo Nordisk
· Noxopharm
· Nyenburgh Holding
· Ohio State University College of Medicine
· Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
· Oklahoma State University
· Omega Funds
· OncoArendi Therapeutics
· Oncology Impact Fund
· OnCore Biopharma
· OrbiMed HealthCare Fund Management
· Oregon Health & Science University
· Cormorant Asset Management
· Osaka City University
· Otsuka Holdings
· Otto von Guericke University Magdeburg
· Pasteur Institute
· Peking University
· Penn State College of Medicine
· Perceptive Advisors
· Pfizer
· Portage Biotech
· Precision for Medicine
· Princeton University
· Providence Cancer Institute
· Purdue University
· Qatar Investment Authority
· Quan Capital
· Queen's University
· RA Capital Management
· Radboudumc
· Rambam Health Care Center
· Recepta Biopharma
· Research Institute of Clinical Medicine
· Roche
· Rock Springs Capital Management
· Rockefeller University
· Roivant Sciences
· Royal Marsden NHS Foundation Trust
· Royal North Shore Hospital
· RTW Investments
· Rush University Medical Center
· Ryvu Therapeutics
· Salk Institute for Biological Studies
· Sanford Burnham Prebys Medical Discovery Institute
· Sanford Cancer Center
· Sanofi
· Sapienza University
· Schrodinger
· Scientipole
· Seoul National Univesity
· Sequoia Capital
· Severance Hospital
· SFPI
· Shandong University
· Shanghai Jiao Tong University
· Shire
· Sichuan Agricultural University
· Sichuan University
· Silicon Therapeutics
· Sirenas
· Sirona Capital
· Smorodintsev Research Institute of Influenza
· SMS-oncology
· Societe Regionale d'Investissement de Wallonie
· SOTIO
· South China Agricultural University
· Southern Medical University
· Spring Bank Pharmaceuticals
· Springhood Ventures
· SR One
· St. Jude Children's Research Hospital
· Saint Louis University School of Medicine
· St. Vincent's Hospital
· Stanford University
· Stimunity
· STINGINN
· Stingray Therapeutics
· STipe Therapeutics
· Stockholm University
· Sun Yat-sen University Cancer Center
· Sunstone Life Science Ventures
· SV Life Sciences
· Swiss Federal Institute of Technology
· Sylvester Comprehensive Cancer Center
· Synlogic
· Takeda Pharmaceutical
· Tbilisi State Medical University
· Technical University of Munich
· Technische Universitat Dresden
· Tempest Therapeutics
· Texas A&M Health Science Center
· The Lind Partners
· Thomas Jefferson University
· Tohoku University
· Tongji University
· Trillium Therapeutics
· Trinity Biomedical Sciences Institute
· Tsinghua University
· ttopstart
· Tufts University
· Tulane University
· TWINCORE-Centre for Experimental and Clinical Infection Research
· Umea University
· UND Life Sciences
· Universidad Autonoma de Madrid
· Universidad Nacional de Rio Cuarto
· Universidade do Porto
· Universidade Federal de Minas Gerais
· Universite de Lyon
· Universite libre de Bruxelles
· University of Alabama Comprehensive Cancer Center
· University of Arizona Cancer Center
· University of Bonn
· University of Buenos Aries
· University of Calgary
· University of California
· University of Cambridge
· University of Chicago
· University of Cincinnati
· University of Clermont Auvergne
· University of Colorado School of Medicine
· University of Connecticut School of Medicine
· University of Delhi
· University of Edinburgh
· University of Ferrara
· University of Florida
· University of Freiburg
· University of Glasgow
· University of Groningen
· University of Hong Kong
· University of Illinois College of Medicine
· University of Kansas
· University of Konstanz
· University of Maryland
· University of Massachusetts Medical School
· University of Miami
· University of Michigan
· University of New South Wales
· University of North Carolina
· University of Orleans
· University of Oxford
· University of Pennsylvania
· University of Piemonte Orientale
· University of Pittsburgh
· University of Queensland
· University of Rhode Island
· University of South China
· University of South Florida
· University of Southern California
· University of Texas MD Anderson Cancer Center
· University of Texas Southwestern Medical Center
· University of Tokyo
· University of Toronto
· University of Utah
· University of Veterinary Medicine Hannover
· University of Virginia
· University of Washington
· University of Zurich
· University of Massachusetts Medical School
· UPMC Hillman Cancer Center
· Uppsala University
· UT Southwestern Medical Center
· Vanderbilt University
· VENENUM Biodesign
· Ventus Therapeutics
· Versant Ventures
· Vertex Ventures
· VIVES Fund
· Vyriad
· Wake Forest School of Medicine
· Washington University School of Medicine
· Wayne State University
· Weill Cornell Medicine
· Weizmann Institute of Science
· Wellington Management Company
· Wikow Invest
· Wuhan University
· WuXi AppTec
· Xi'an Jiaotong University
· Xi'an Medical University
· Xuzhou Medical University
· Yale Cancer Center
· Yangzhou University
· Yokohama City University
· York University
· Zhejiang University School of Medicine
· Zhengzhou University

For more information about this report visit https://www.researchandmarkets.com/r/ui37z3

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900